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Abstract
 
The immune response against hepatitis C virus (HCV) is rarely effective at clearing the virus,
resulting in 
 
 
 
170 million chronic HCV infections worldwide. Here we report that ligation of
an HCV receptor (CD81) inhibits natural killer (NK) cells. Cross-linking of CD81 by the ma-
jor envelope protein of HCV (HCV-E2) or anti-CD81 antibodies blocks NK cell activation,
cytokine production, cytotoxic granule release, and proliferation. This inhibitory effect was
observed using both activated and resting NK cells. Conversely, on NK-like T cell clones, in-
cluding those expressing NK cell inhibitory receptors, CD81 ligation delivered a costimulatory
signal. Engagement of CD81 on NK cells blocks tyrosine phosphorylation through a mecha-
nism which is distinct from the negative signaling pathways associated with NK cell inhibitory
receptors for major histocompatibility complex class I. These results implicate HCV-E2–medi-
ated inhibition of NK cells as an efficient HCV evasion strategy targeting the early antiviral
activities of NK cells and allowing the virus to establish itself as a chronic infection.
Key words: natural killer cells • inhibitory signaling • immune evasion • chronic viral 
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Introduction
 
All pathogens have evolved specific mechanisms to under-
mine host defenses. The evasion strategies of those patho-
gens which give rise to chronic infections can be remark-
ably sophisticated given the need to circumvent multiple
arms of the immune system over years-decades of infec-
 
tion (1). Hepatitis C virus (HCV)
 
*
 
 gives rise to chronic
liver infections and is the leading cause of chronic liver
disease (2). A hallmark of HCV-associated liver pathology
is a massive lymphocyte infiltrate in the infected organ (3,
4). Despite this apparently aggressive immune response,
spontaneous resolution of chronic HCV is exceedingly
rare, suggesting that HCV actively evades and/or directly
limits the effectiveness of this immune response. Recent
studies have implicated the HCV-E2 protein as a central
component of two potential HCV evasion mechanisms (5,
6). Thus, the HCV-E2 protein appears to play at least two
distinct roles in thwarting the immune response mounted
against the virus.
NK cells are lymphocytes active in innate immune re-
sponses against viruses, as well as, bacteria and tumors, due
to their potent cytotoxic activities and rapid production of
cytokines (7). During the early immune response, NK cell
functions are regulated by cytokine feedback loops and di-
rect interaction with infected or transformed cells which
are targets of their cytotoxicity. The specificity of NK–tar-
get interactions is determined by a balance between stimu-
latory and inhibitory receptors (8). The NK stimulatory re-
ceptors and their ligands on target cells are a heterogeneous
class of surface molecules whose usage can vary depending
on the target cell type and activation state of the NK cell
(8). The less specific interactions between stimulatory NK
receptors and their target cell ligands are kept under control
by diverse families of well characterized NK inhibitory re-
ceptors for MHC class I (8).
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HCV-E2 Inhibits NK Cells
 
The HCV-E2 protein binds the human cell surface mol-
ecule CD81 with high affinity, indicating that CD81 may
function as a cellular receptor for the virus (9). CD81 be-
longs to a family of molecules called tetraspanins, character-
ized by four transmembrane domains forming two extra-
cellular loops (10). The major loop of CD81 is necessary
and sufficient for binding to HCV-E2 (9). CD81 is found
on the surface of almost all nucleated cells where it is a
component of multiple and distinct receptor complexes de-
pending on the cell type (10). Recent studies have shown
that ligation of CD81 with antibodies or HCV-E2 costim-
ulates T cells (11). Here we demonstrate that unlike T cells,
CD81 ligation by HCV-E2 potently inhibits NK cell func-
tions through a novel negative signaling mechanism. These
results provide the first demonstration of an HCV immune
escape mechanism specifically targeting the early antiviral
responses of NK cells. In addition, they shed new light on
fundamental differences between T and NK cell signaling
pathways and a potentially dual role of CD81 on the two
cell types.
 
Materials and Methods
 
Antibodies and Reagents.
 
Antibodies used were: anti-CD3
(clones OKT-3 and TR-66; American Type Culture Collection),
anti-CD16 (3G8, American Type Culture Collection), anti-
CD56 (B159.5, provided by G. Trinchieri, Schering Plough Re-
search Institute, Dardilly, France), anti-CD81 (JS-81; BD Phar-
Mingen), anti-HLA class I (W6/32; Serotec), anti–HCV-E2
(provided by D. Rosa, Chiron S.p.A., Siena, Italy), anti–IFN-
 
 
 
(B133.1 and B133.5), anti–TNF-
 
 
 
 (B145.9 and B154.7) were
both provided by G. Trinchieri. The antiphosphotyrosine (4G10;
Upstate Biotechnology, Inc.), anti-p42/p44 erk-2, anti-phospho
p42/p44 erk-2 (Cell Signaling Technology), and anti-CD3
 
 
 
chain (6B10.2; Santa Cruz Biotechnology, Inc.) were used for
immunoprecipitation and Western blot analysis.
 
Cell Preparation and Cultures.
 
PBMCs were prepared from
peripheral blood by Ficoll-Paque density gradient centrifugation,
followed by 1-h incubation in plastic flask to remove adherent
monocytes. Cultured NK cells were prepared as described previ-
ously (12). All cultures were collected at days 8–10. NK cells
(
 
 
 
98% CD56
 
 
 
/CD3
 
 
 
/CD19
 
 
 
/CD14
 
 
 
) were purified by deple-
tion of the magnetically labeled CD3
 
 
 
/CD14
 
 
 
/CD19
 
 
 
 cells us-
ing MACS
 
®
 
 Separation Columns (Miltenyi Biotec). NK and T
cell clones were generated and maintained as described previously
(13). In brief, PBMCs were stained with antibodies for CD3,
CD56, killer Ig-like receptor (KIR)2DL/S1 (EB6, CD158a;
Immunotech), KIR2DL/S2 (GL183, CD158b; Immunotech),
KIR3DL1 (NKB1, DX9; Becton Dickinson), KIR3DL2
(NKAT4, DX31, provided by L. Lanier, University of California
at San Francisco, San Francisco, CA) TCR V
 
 
 
24 (C15; Immu-
notech), and/or TCR V
 
 
 
11 (C21; Immunotech) and the desired
subpopulations were single-cell sorted using a FACSVantage™
SE
 
®
 
 cell sorter (Becton Dickinson) in 60-well Terazaki plates
(Robbins Scientific). To expand NK T cells, cells were activated
with 
 
 
 
-GalCer (100 
 
 
 
g/ml in 100% DMSO) at the final concen-
tration of 30–100 ng/ml (14).
 
Antibody Coating and Cell Stimulation.
 
The following puri-
fied mAb were used in stimulation experiments: anti-CD16
(3G8), anti-CD3 (TR-66), anti CD81 (JS-81), anti E2 (291A2),
anti-CD56 (B159.5), anti-HLA class I (W6/32). 96-well plates
(Greiner) were coated as described previously (11). The recombi-
nant purified HCV E2 protein (10 
 
 
 
g/ml in PBS) was incubated
in the coated anti-E2 mAb (10 
 
 
 
g/ml) plates for 1 h at 37
 
 
 
C.
Prior to the addition of cells the excess HCV-E2 was removed by
washing in PBS.
 
Immunofluorescence Assays.
 
Antibodies used for flow cytome-
try were the following: anti-CD3, anti-CD56, anti CD16, NKB1
(KIR3DL1), anti–IFN-
 
 
 
, and anti–IL-4 (all Becton Dickinson).
Anti-CD158a (KIR2DL/S1), anti-CD158b (KIR2DL/S2), anti-
TCR V
 
 
 
24 (C15), and anti-TCR V
 
 
 
11 (C21) were from Im-
munotech. Cells were analyzed on a FACSCalibur™ flow cy-
tometer (Becton Dickinson) using CELLQuest™ software.
 
Cytokine Production Assays.
 
Purified NK cells were cultured
in 96-well coated plates for 24 and 48 h and the supernatants
were assessed by ELISA for IFN-
 
 
 
 and TNF-
 
 
 
. The capture an-
tibodies were anti–IFN-
 
 
 
 mAb B133.1 and the anti–TNF-
 
 
 
mAb B154.9, respectively, which were immobilized on ELISA
plates. Detection of each cytokine was achieved using biotiny-
lated anti–IFN-
 
 
 
 mAb B133.5 and anti–TNF-
 
 
 
 mAb B154.7,
streptravidin-conjugated peroxidase (Sigma-Aldrich), and the
chromogenic substrate o-phenylenediamine dihydrochloride
(Sigma-Aldrich). Spectrophotometric analysis was performed at
450 nm on a Spectramax 340 spectrophotometer (Molecular De-
vices) using Softmax Pro software (Molecular Devices).
 
N-carbobenzoxy-L-thiobenzyl Ester Esterase Assay.
 
The amount
of secreted N-carbobenzoxy-L-thiobenzyl ester (BLT)-esterase
was measured using 10
 
5
 
 purified cultured NK cells in 100 
 
 
 
l of
complete medium in a 96-well ELISA plate coated with the indi-
cated mAb, as described previously (15). After 4-h incubation at
37
 
 
 
C, 5% CO
 
2
 
, 50 
 
 
 
l of cell-free supernatant fluids were added
to 100 
 
 
 
l of BLT solution (0.2 mM BLT, 0.22 mM 5,5
 
 
 
-dithio-
bis-[2-nitrobenzoic acid]; DTNB) in PBS. BLT-esterase activity
was measured by absorbance at 405 nm. Total BLT-esterase ac-
tivity was determined from lysed (freeze/thaw three times) un-
treated NK cells.
 
Proliferation Assays.
 
NK cell proliferation was assessed by
 
3
 
[H] thymidine incorporation using 2 
 
 
 
 10
 
4
 
 cells per well in
mAb-coated 96-well plates. Cultures were pulsed after 48 h
with Ci/well 
 
3
 
[H] thymidine, incubated for an additional 12 h,
harvested onto filter plates (Packard Instrument Co.), and
counts were analyzed using a Top Count NXT 
 
 
 
 counter
(Packard Instrument Co.).
 
Immunoprecipitation and Immunoblot Analysis.
 
Purified NK
cells (10
 
7
 
 per sample for immunoprecipitation or 10
 
6
 
 per sample
for whole-cell extracts) were incubated on ice for 5 min with
anti-CD16 mAb (3G8), anti-CD81mAb (JS-81, 10 
 
 
 
g/ml), or
anti-CD56 mAb (B159.5, 10 
 
 
 
g/ml). Cells were then washed
and incubated with goat anti–mouse IgG F(ab)
 
 
 
2
 
 fragments
(Sigma-Aldrich) at 30 
 
 
 
g/ml at 37
 
 
 
C for the indicated time. Cells
were lysed in buffer containing 20 mM Tris-HCl, pH 7.4, 40
mM NaCl, 5 mM EDTA, 1 mM NaF, 20 mM Na
 
4
 
P
 
2
 
0
 
7
 
, 1 mM
Na
 
3
 
VO
 
4
 
, 0.1% BSA, 1 mM PMSF, 5 
 
 
 
g/ml aprotinin, 10 
 
 
 
g/ml
leupeptin, and 1% Triton X-100. In some experiments, whole
cell extracts were resolved by SDS-PAGE. For immunoprecipita-
tions, cell lysates were incubated for 18 h with the appropriate Ab
(4G10 for phosphotyrosines, 6B10.2 antibody for the 
 
 
 
-chain)
and then for 1–2 h with protein A or G –Sepharose (Upstate Bio-
technology, Inc.). The immunoprecipitates were resolved by
SDS-PAGE and transfered to nitrocellulose membranes (Sigma-
Aldrich). Tyrosine-phosphorylated proteins were detected with
the 4G10 mAb, followed by sheep anti–mouse IgG coupled to
horseradish peroxidase (Amersham Pharmacia Biotech) and the
Supersignal detection system (Pierce Chemical Co.). The p42/ 
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p44 and phospho p42/p44 mitogen-activated protein kinases
(MAPKs) were detected using Cell Signaling Technology anti-
bodies, followed by donkey anti–rabbit IgG coupled to horserad-
ish peroxidase (Amersham Pharmacia Biotech).
 
Results
 
The Effect of CD81 Ligation on NK Cell Function.
 
Pre-
vious results from our group indicated a substantial enrich-
ment of NK cells in HCV-infected livers and their altered
expression of KIRs (4, 16). Given the role of CD81 as both
an HCV attachment receptor with high affinity for HCV-
E2 and a functionally relevant molecule on lymphocytes
(9–11), we developed an in vitro model to study the effects
of HCV-E2 binding to CD81 on NK cells. We first ad-
dressed whether cross-linking NK cell CD81 altered NK
cell functions induced by the NK cell triggering receptor
CD16 (Fig. 1). CD16 is the low affinity receptor for IgG
(Fc
 
 
 
RIII) and is considered the best characterized and most
potent stimulatory receptor found on NK cells (7). Using
highly purified NK cells obtained from bulk culture, we
observed that CD16-induced TNF-
 
 
 
 and IFN-
 
 
 
 produc-
tion (Fig. 1 A and B) was inhibited strongly by coligation
of NK cell CD81 with HCV-E2. Similarly, HCV-E2
cross-linking of CD81 blocked CD16-mediated induction
of NK cell activation marker (CD25) expression (Fig. 1 C)
and cytotoxic granule release (Fig. 1 D). In addition, liga-
tion of CD81 on NK cells substantially inhibited their ca-
pacity to proliferate in response to IL-2, demonstrating that
the inhibitory effect is not only active on CD16-induced
signals (Fig. 1 E). A similar inhibitory effect of CD81 en-
gagement was seen on NK cell IFN-
 
 
 
 production in re-
sponse to treatment with IL-2, IL-12, or a combination of
both (data not shown).
In all experiments cross-linking with an anti-CD81 mAb
mimicked the inhibition observed with HCV-E2 and no
inhibition of NK cell functions induced through CD16 li-
gation was seen after cotreatment with the control reagents.
In addition, anti-CD81 or HCV-E2 cross-linking in the
absence of CD16 stimulation had no effect on any of the
NK cell functions tested. The inhibitory effect of CD81
cross-linking was not due to toxicity of the HCV-E2 or
anti-CD81 reagents because neither treatment effected NK
cell survival under all of the conditions tested in Fig. 1.
Specifically, flow cytometric analyses of NK cell viability,
measured by propidium iodide uptake, or apoptosis deter-
mined by annexin V staining, revealed no increased NK
cell death in response to CD81 ligation (data not shown).
Resting NK cells were also inhibited by CD81 ligation.
Freshly isolated PBMCs were incubated with anti-CD16
Figure 1. Cross-linking of
CD81 by HCV-E2 or anti-CD81
antibody blocks NK cell activa-
tion, cytokine production, and
cytotoxic granule release in-
duced by CD16 and IL-2 in-
duced proliferation. Purified,
cultured NK cells were stimu-
lated for 24 or 48 h and the su-
pernatants were analyzed for cy-
tokine (TNF-  or IFN- )
production (A and B). NK cells
were stimulated for 24 h and
then analyzed by flow cytometry
to evaluate the expression level
of the activation marker CD25
(C). 105 purified NK cells were
stimulated for 4 h and superna-
tants were assayed for BLT-ester-
ase activity which is defined as
the percentage of the total BLT-
esterase activity obtained from
the same number of lysed NK
cells (D). For these experiments
(A–D) NK cells were cultured in
the presence of the indicated
concentrations of the anti-CD16
antibody alone ( ) or in combi-
nation with 10  g/ml of: anti-
CD56 ( ); anti–HCV-E2 ( );
anti-CD81 ( ) or anti–HCV-
E2   rHCV-E2 ( ). In E, NK
cell proliferation in the presence
or absence of rIL-2 was deter-
mined by 3[H]thymidine incorporation. NK cells were cultured at the indicated doses of rIL-2 alone ( ) or in combination with 10  g/ml of: anti-
CD56 ( ); anti-HCV-E2 ( ); anti-CD81 ( ) or anti–HCV-E2   rHCV-E2 ( ). Experiments to determine the optimal concentrations of anti-CD81
or anti–HCV-E2   rHCV-E2 required for NK cell inhibition, demonstrated that the negative effect was detectable over a broad range of concentrations
(2.5–20  g/ml), with 10  g/ml giving the most potent and consistent inhibition compared with controls (data not shown). 
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mAb alone or in combination with the different anti-CD81
or control reagents used in the experiments of Fig. 2. The
NK cells from the mixed PBMC populations were ana-
lyzed by flow cytometry via specific gating on the CD56
 
 
 
/
CD3
 
 
 
 NK cell subset (Fig. 2). Again, the effect of CD81
cross-linking was potent inhibition of CD16-induced IFN-
 
 
 
production (Fig. 2 A, C, and E) and activation marker
(CD25) expression. (Fig. 2 B, D, and F). Thus, resting NK
cells are inhibited by CD81 engagement similar to the pu-
rified/activated NK cells obtained from bulk culture. This
suggests that early in the immune response against HCV
and before NK cells are fully activated, binding of HCV-
E2 to NK cell CD81 has the potential to dampen signifi-
cantly the rapid antiviral responses of NK cells.
 
Opposing Effects of CD81 Ligation on NK Cells and T
Cells.
 
NK cells and T cells share many phenotypic and
functional features (17). Small subsets of T cells also ex-
press characteristic NK cell markers such as CD16 and
CD56. In addition, KIR
 
 
 
 T cells can be isolated from the
blood of healthy individuals and these T cells are inhibited
by KIR recognition of HLA class I ligands, similar to what
is routinely observed for NK cells (18). A previous report
from Wack et al. demonstrated that bulk populations of T
cells were costimulated by CD81 cross-linking, however
this study did not investigate T cells bearing NK cell re-
ceptors (11). Therefore, we generated T and NK cell
clones from healthy individuals and compared their re-
sponses after CD81 engagement (Fig. 3). Similar to our
previous results with cultured or resting NK cells, the NK
cell clones were all inhibited by CD81 cross-linking either
with an anti-CD81 mAb or HCV-E2 (Fig. 3 A). By con-
trast, none of the T cell clones tested, representing six dis-
tinct phenotypic/functional subsets, were inhibited after
simultaneous ligation of CD81 and CD3 (Fig. 3 B and C).
In fact, 5 out of the 6 subsets tested (TCR 
 
  
 
 
 
 “classical”;
KIR
 
 
 
; NKT; Th1; and Th2 T cell clones) were all co-
stimulated by simultaneous CD81 and CD3 engagement
similar to previous results using bulk populations of resting
T cells and PHA-activated T cell lines (11). The one ex-
ception was found using a rare and understudied popula-
tion of T cells bearing the characteristic NK marker,
CD16 (19). Unlike NK cells and other T cells, the re-
sponse of these cells to cocross-linking of CD3 and CD81
on their surface was neutral. This failure of CD81 ligation
to elicit any response in CD16
 
 
 
 T cells was observed
when we measured CD3-induced IFN-
 
 
 
 (Fig. 3 C) and
TNF-  production, as well as, CD3-mediated prolifera-
tion and activation marker expression (data not shown).
Ligation of CD16 on these T cell clones had no effect,
consistent with a previous report (20).
Inhibition of CD16-mediated Tyrosine Phosphorylation by
CD81 Engagement. The activation of protein tyrosine ki-
nases (PTKs) and their phosphorylation of diverse substrates
is a necessary event in NK cell activation through CD16
and other NK triggering receptors (21, 22). Therefore, we
examined the capacity of CD81 cross-linking to block this
critical signaling pathway. Analysis of total PTK activity
was performed by determining the extent of phosphoty-
rosine (p-Tyr) substrates induced in NK cells by CD16
cross-linking alone or in combination with anti-CD81 or
anti-CD56 treatment. The overall p-Tyr levels induced
through CD16 were substantially diminished after simulta-
neous ligation of CD81 (Fig. 4 A). The examination of
specific PTK substrates known to be phosphorylated in NK
cells as a result of CD16 stimulation and important for
CD16-induced functions yielded similar results (Fig. 4 B
and C). Specifically, we chose for this analysis: (i) CD3 
which is directly associated with CD16 in NK cells and
whose phosphorylation is induced immediately proximal to
CD16 ligation (23); and (ii) erk-2 that is part of the more
downstream MAPK cascade important for NK cell cyto-
kine gene expression and proliferation (24). The tyrosine
phosphorylation of both signaling moieties was specifically
inhibited after CD81 ligation. In addition, cross-linking
with the anti-CD81 or anti-CD56 reagents alone had no
effect on the extent of phosphorylated proteins detected in
the NK cells in all of the experiments.
We initiated a series of studies investigating the potential
association of CD81 with KIR and the inhibitory signaling
phosphatases, src homology 2 domain–bearing protein ty-
rosine phosphatase (SHP)1 and SHP2 (25), by performing
coimmunoprecipitation/Western blotting experiments us-
Figure 2. CD81 engagement blocks the
functions of resting NK cells. PBMCs
freshly purified from healthy donors were
cultured in complete medium on plastic
plates coated with no antibody (A and B), 1
 g/ml of CD16 mAb alone (C and D), or 1
 g/ml of CD16 mAb plus 10  g/ml of
CD81 mAb (E and F). After 4 h of Brefel-
din-A treatment, cells were stained for in-
tracellular IFN-  production (A, C, and E)
and for the surface expression of the activa-
tion marker CD25. The plots in (A–F) rep-
resent the CD3-CD56  subpopulation as
defined by the staining in H. In G, CD16
stimulation is specific for NK cells as the
CD3  (T cell) PBMC subpopulation did
not produce any IFN- , as assayed by intra-
cellular staining.39 Crotta et al.
ing anti-KIR, anti-SHP, and anti-CD81 anitbodies to de-
tect specific complexes formed on the surface of NK cells.
Studies were performed on unstimulated NK cells and
those treated with anti-CD16 antibody alone or in combi-
nation with anti-CD81. Under all conditions the results of
these analyses were negative indicating that a specific asso-
ciation between the HLA class I inhibitory receptor system
and CD81 is unlikely (data not shown). This conclusion is
also supported by the fact that KIR  T cells which possess
the capacity to be inhibited by HLA class I recognition
through the KIR-SHP pathway (18) are not inhibited by
CD81 ligation but rather costimulated by it (Fig. 3). In ad-
Figure 3. CD81 cross-linking has opposite effects on NK and T cells.
NK (A) and T (B) cell clones from the same healthy donor were stimu-
lated for 24 h and the supernatants were analyzed for the presence of IFN- .
The NK cell clones (A) were stimulated with the indicated concentrations
of anti-CD16 alone ( ) or in combination with 10  g/ml of: anti-CD81
( ) or anti-HCV-E2   rHCV-E2 ( ). The “classical” TCR     T cell
clones (B) were stimulated with decreasing concentrations of anti-CD3
alone ( ) or in the presence of 10  g/ml: anti-CD81 ( ) or anti–HCV-
E2   rHCV-E2 ( ). Control antibodies for anti-CD56 (NK cells) or
anti-class I (T cells) had no effect and neither did treatment with the anti-
HCV-E2 reagent alone (data not shown). In (C) the effects of CD81 liga-
tion on different T and NK cell subsets is summarized. NKT (gray bar),
KIR  T (stippled bar), CD16  T (hatched bar), Th1 (striped bar), Th2
(white bar, and NK cell (black bar) clones were obtained from the same
healthy donor by single cell sorting. The scheme represents the effect of
CD81 cross-linking on these different cell types when activated by the
appropriate stimulus (anti-CD16 mAb for NK cells, anti-CD3 mAb for
the other T cell types). Cytokine production (IFN- : KIR  T; Th1;
CD16  T, NK or IL-4: Th2 cell clones), or proliferation (NKT) were
used as readouts for CD81-mediated costimulation or inhibition. Results
are presented as percentage change compared with treatment with 0.3
 g/ml of anti-CD16 (NK cells) or anti-CD3 (T cells). CD16  T cells
were also analyzed for proliferation, their ability to produce TNF-  and
their expression of activation markers after CD81 ligation. In all cases this
treatment had no effect (data not shown).
Figure 4. CD81 engagement inhibits specific CD16-triggered tyrosine
phosphorylation events. Purified, cultured NK cells (107 per sample) were
incubated with the indicated antibodies for 1 min and tyrosine phos-
phorylated proteins were immunoprecipitated from cell lysates, resolved
by SDS-PAGE, transferred to a nitrocellulose membrane and immuno-
blotted with antiphosphotyrosine mAb (A). NK cells (107 per sample)
were stimulated with the indicated cross-linked mAb’s for 1 or 3 min, as
indicated in the figure (B and C). Total cell lysates were resolved by SDS
PAGE and immunoblotted (B) first with a rabbit polyclonal antiphospho-
p44/42 MAPK (erk-2) antibody (top) and then reprobed with a rabbit
polyclonal p44/42 MAPK (erk-2) antibody (bottom). Under the same
conditions cell lysates were subjected to immunoprecipitation with anti- 
polyclonal antibody (C). Immunoprecipitated proteins were immuno-
blotted first with antiphosphotyrosine mAb (top) and then with the im-
munoprecipitating polyclonal antibody (bottom). In these experiments,
SDS-PAGE was performed in nonreducing conditions to detect the
32 kD   homodimers ( 2).40 HCV-E2 Inhibits NK Cells
dition, ligation of CD81 blocks NK cell responses to solu-
ble factors which has not been observed for other NK in-
hibitory receptor systems.
Discussion
NK cells provide a critical first line of defense against vi-
ral infections through their rapid and potent cytotoxic ac-
tivity and production of inflammatory cytokines such as
IFN-  (26). However, no role for NK cells in the anti-
HCV immune response has ever been established. We de-
scribe that the binding of the HCV envelope protein,
HCV-E2, to CD81 directly blocks NK cell functional acti-
vation. Thus, HCV possesses a mechanism which specifi-
cally downregulates the NK cell response, providing the vi-
rus with an efficient immune-escape strategy capable of
limiting the antiviral activities of NK cells early in the in-
fectious process. This novel mechanism could be critical in
determining the viruses ability to gain a foothold in the
host and establish itself as a chronic infection.
The direct inhibition of NK cells via binding of HCV-E2
to CD81 provides a global “off” signal for NK cell activa-
tion and efficiently blocks cytokine production, activation
marker expression, cytotoxic granule release, and prolifera-
tion. CD81-mediated inhibition of NK cells was seen for
activated and resting NK cells and in NK cells from healthy
donors and patients suffering from chronic HCV infections
(data not shown), suggesting that the inhibitory effect is a
general function of NK cell CD81 and could occur at all
stages of infection. The functional inhibition can be ex-
plained by the fact that CD81 engagement blocks tyrosine
phosphorylation of important upstream and downstream
signaling moieties induced by cross-linking CD16. How-
ever, the inhibitory signals generated after CD81 ligation
appear independent of the well characterized SHP-medi-
ated negative signaling pathway associated with NK cell
and other inhibitory receptor systems (25). Thus, CD81
participates in a previously unrecognized negative signaling
pathway of NK cells.
T cell clones representing distinct functional and pheno-
typic subsets, including those with NK-like properties,
were not inhibited by CD81 ligation. In fact, almost all of
the different T cell subpopulations studied were costimu-
lated by the interaction, similar to a previous report where
bulk populations of T cells were used (11). Furthermore, a
different study has shown that CD81 ligation on TCR    
T cells is also costimulatory rather than inhibitory (27).
This finding whereby the same surface molecule mediates
completely opposing effects on NK cells and T cells is un-
precedented and raises fundamental questions about the
immunobiology of CD81; NK versus T cell signaling; and
how HCV exploits these differences to confound both NK
and T cell responses and establish itself as a chronic infec-
tion. Intriguingly, a similar inhibitory effect of CD81 liga-
tion on basophils has been reported (28). The mechanism
of this inhibition was not well characterized but appeared
to be distinct from other known inhibitory pathways and
similar to the inhibition of NK cells reported here (28). It is
likely that CD81 inhibits NK cells and basophils through a
common mechanism. The larger question of why NK cells
and T cells which share so many phenotypic and functional
characteristics (17) differ so dramatically in their responses
to CD81 engagement still remains open for investigation. It
is possible that distinct inhibitory or stimulatory receptors
which differentially associate with CD81 on the two cell
types govern these unique responses. Alternatively, a more
fundamental difference in the intracellular signaling re-
quirements of T and NK cells, and an inhibitory bias of the
NK cell signaling machinery could explain the dual func-
tional outcomes of CD81 ligation.
Infection with HCV is a major health problem world-
wide. There is no therapy which is effective at eliminating
established HCV infections in the majority of patients and
prophylactic vaccine candidates are just beginning to enter
clinical trials (16, 29). The study of HCV and, therefore,
the design of effective treatments and vaccines is hampered
by many technical obstacles. Two of the most important of
which are the lack of in vitro culture systems and small an-
imal models (30). These barriers render it difficult to study
the virus and its associated pathologies directly. To over-
come these limitations it has been necessary to develop
novel experimental systems which shed light on HCV biol-
ogy and pathogenesis. One such system employed the re-
combinant HCV-E2 protein to identify the high affinity
interactions of this envelop protein and the virus itself with
human CD81 (9). Using this model system we have un-
covered a role for the HCV-E2:CD81 interaction which
could function as an immune escape mechanism for the vi-
rus and explain how HCV is so adept at establishing itself as
a chronic infection. Although it is currently impossible to
measure directly how NK cell responses are affected upon
binding to HCV-infected cells or the virus itself, our results
presented suggest that such an encounter in vivo would
suppress significantly NK cell functions. Given that the
HCV-E2 protein is expected to be present at high copy
number on HCV viral particles, the cross-linking of CD81
required for inhibition should be comparable to the anti-
body-mediated cross-linking reported here. However, fur-
ther study of the potential inhibitory effects of HCV on
NK cells is clearly warranted and it will be particularly im-
portant to establish the physiologic relevance of NK cell in-
hibition via HCV-E2 binding to CD81. In conclusion,
these findings not only provide important new insights into
HCV immune evasion and the role of NK cells in the anti-
HCV response, but also into the unique functions of CD81
and the divergent signaling mechanisms of NK and T cells.
It will be important in the future to investigate each of
these new research avenues both in the context of HCV
immune escape and in the more general framework of T
and NK cell biology.
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